secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069198
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics reduces workforce by ~30% to retain ~23 employees
-----------------------------------------------------------------------

- Approximately 30% workforce reduction, retaining ~23 employees; expected completion by August 2025.
- Expected severance and related costs of $1.4 million in one-time cash charges.
- Additional details to be provided in the Q2 2025 10-Q filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025069198/0000950170-25-069198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025069198/atra-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer